Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Campral | Acamprosate calcium | Alcohol Abstinence | List with clinical criteria and/or conditions | Complete | ||
Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete | ||
Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | ||
Alecensaro | alectinib | ALK-positive NSCLC | Active | |||
Oralair | Grass Pollen Allergen Extract | Allergic rhinitis | List with criteria/condition | Complete | ||
Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | ||
Olumiant | baricitinib | Alopecia areata, severe | Active | |||
Leqembi | lecanemab | Alzheimer’s disease | Pending | |||
Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn |